PF-07038124

DB19143InvestigationalSmall molecule

PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).

Mechanism: Pharmacologically active on Phosphodiesterase 4
Curator reviewed
Formula / weight: C₁₈H₂₂BNO₄ · 327.19 g/mol (avg)
Code names: PF-07038124

Resolves to

Compound

UNIIM6ZU548FWDCAS2415085-44-6

Structure

InChIKeyKXVKOYCGACSUPP-INIZCTEOSA-NSMILES[H][C@]1(COB(O)C1)C1=CN=CC(=C1)C1=CC=C(OC)C(OCCC)=C1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of PF-07038124, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account